Nordic Life Science 1
Helena Strigård, Director General, SwedenBIO SWE
D EN was published one year ago and the two surveys demonstrate the strength and resilience of the sector, states SwedenBIO. The survey targeted pharmaceutical development companies with operations in Sweden and 80% of the companies reported they intend to recruit more staff or consultants in the coming year. Compared to the situation a year ago, their confidence in projecting future growth has increased and 62% of companies have a more positive view of their projections now compared to before COVID-19 hit, with only 8% reporting the opposite. The survey also revealed an increasing number of international experts being appointed to boards and collaborations being signed. There have been delays and issues for some e.g., when it comes to recruiting patients to clinical trials and raising capital. However, at the same time, some companies saw new opportunities and wanted to contribute to the development of better tests or treatments for COVID-19.